表紙
市場調査レポート

癌検査における分子診断

Molecular Diagnostics in Cancer Testing

発行 TriMark Publications 商品コード 203890
出版日 ページ情報 英文 201 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
癌検査における分子診断 Molecular Diagnostics in Cancer Testing
出版日: 2016年06月06日 ページ情報: 英文 201 Pages
担当者のコメント
米国ニューヨークに本社を置くTriMark Publicationsは、医療分野の市場分析に定評のある調査会社です。アメリカ市場の分析を得意としており、本レポートでもアメリカの主要な企業の情報が網羅されております。TriMark Publicationsが発行するレポートは、比較的短いスパンで情報が更新される商品が多く、最新データが網羅されているとして継続的に購入されるお客様の多い人気のシリーズです。
概要

分子診断は急速に進化している分野で、新しい技術や応用が次々に登場しています。分子診断に含まれる技術には、第1世代の増幅、DNAプローブ、蛍光in-situハイブリダイゼーション (FISH)、第2世代のバイオチップとマイクロ流体、次世代の信号検出、バイオセンサー、分子ラベル、マイクロアレイを用いた遺伝子発現プロファイリングなどがあります。これらの技術は癌の治療分子を発見し、癌患者のスクリーニングや診断、分類、そして投薬治療の最適化に大きく貢献しています。

当レポートでは、分子診断として知られる体外診断分野について詳細に分析し、癌の検知や治療に用いられる分子診断市場の規模と成長動向などについてまとめ、その結果をお届けいたします。

第1章 概要

第2章 分子診断のイントロダクション

  • 分子診断の機会創出
  • ヒトゲノムプロジェクトが分子診断に及ぼす影響
  • 分子および臨床診断に関する考察
  • ポストゲノム時代における分子診断
  • 分子診断技術の進歩
  • オリゴヌクレオチドアレイプラットフォーム
  • 新興の癌個別化医療市場
    • 予測的癌分子診断
  • 薬剤開発のためのコンパニオン検査
  • 分子診断企業の機会
  • リキッドバイオプシー
  • データ分析
  • 社内/商用試験
  • 癌の多重遺伝子パネル検査

第3章 癌診断のための分子検査市場

  • 市場の概要
    • 市場の概略
    • 癌検査のための分子診断を行う研究所
    • 競合環境
    • 癌検査の売上高とマーケティング戦略

第4章 癌の分子診断検査

  • 癌診断検査
    • 癌の治療戦略
    • 癌の治療
    • 癌を理解するためのゲノミクスの利用
    • 分子診断ツールソリューション
    • 遺伝子発現分析技術
  • 乳癌
    • 乳癌の概要
    • 乳癌の分子診断アッセイ
    • 競合構造と市場シェア分析
    • 市場促進・抑制要因
    • 乳癌の分子診断検査分析市場および技術
  • 結腸直腸癌の分子診断市場
    • 結腸癌の概要
    • 結腸癌の分子診断アッセイ
    • 競合構造と市場シェア分析
    • 結腸癌の分子検査に関する新しいガイドライン前立腺癌の分子診断市場
    • 分子スクリーニング分析
    • 直腸結腸生検後に実施する分子アッセイ
    • 競合構造と市場シェア分析
    • 市場促進・抑制要因
    • 前立腺癌の分子診断検査の検定市場と技術動向
  • 卵巣癌
    • 卵巣癌の発生率
    • 卵巣癌検査市場の主要企業
  • 肺癌
    • 肺癌の発生率
    • 薬理ゲノム学と癌
    • 肺癌の分子診断アッセイ
    • 競争空間
  • 黒色腫 (メラノーマ)
    • bioMerieux
    • Roche
    • Myriad
    • Trovagene
  • その他の癌のための分子診断アッセイ
    • Accugenomics
    • Ambry Genetics
    • Asuragen
    • DiaSorin
  • 多発性癌検査パネル
  • 潜在的市場新規参入者

第5章 ビジネス

  • 技術・市場の動向
  • M&A活動
  • 提携
  • SWOT分析
    • 産業の課題と戦略的提言
    • 分子診断製品の実用化
  • 知的財産権

第6章 償還と請求

  • 概要
  • 償還手法の傾向
  • 患者ケアと償還
  • 収益面の脅威
  • 請求

第7章 政府の規制

第8章 企業プロファイル (41社)

付録1:分子診断関連の用語の定義

付録2:標準的な癌診断パネル

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: TMRMDC16-0601

Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added. The technologies that come under the umbrella of molecular diagnostics include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays. These technologies are improving the discovery of therapeutic molecules for cancer, the screening, diagnosis and classification of cancer patients, and the optimization of drug therapy. This TriMark Publications report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for cancer. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of cancer. This report analyzes the size and growth of the molecular diagnostics market in its applications for cancer detection and therapy, examining the factors that influence the various market segments and the dollar volume of sales, both in the United States and worldwide.

Table of Contents

1. Overview

  • 1.1 Statement of Report
  • 1.2 About This Report
  • 1.3 Scope of the Report
  • 1.4 Objectives
  • 1.5 Methodology
  • 1.6 Executive Summary

2. Introduction to Molecular Diagnostics

  • 2.1 Opening of Opportunities in Molecular Diagnostics
  • 2.2 Impact of the Human Genome Project on Molecular Diagnostics
  • 2.3 Considerations for Molecular and Clinical Diagnostics
  • 2.4 Molecular Diagnostics in the Post-Genomic Era
  • 2.5 Advances in Molecular Diagnostics Technologies
    • 2.5.1 Molecular Methods to Detect Genetic Variants in Cancer
      • 2.5.1.1 Allele-Specific PCR
      • 2.5.1.2 Sanger Dideoxy Sequencing
      • 2.5.1.3 Pyrosequencing
      • 2.5.1.4 Mass Spectrometry
      • 2.5.1.5 Single Base Extension Assay
      • 2.5.1.6 Multiplex Ligation-Dependent Probe Amplification (MLPA)
      • 2.5.1.7 Fluorescence In Situ Hybridization (FISH)
      • 2.5.1.8 Next Generation Sequencing
        • 2.5.1.8.1 Next-Generation Sequencing-Custom Panels, Amplicon Capture
        • 2.5.1.8.2 Next-Generation Sequencing-Custom Panels, Hybridization Capture
        • 2.5.1.8.3 Next-Generation Sequencing-Whole Exome Sequencing
        • 2.5.1.8.4 Next-Generation Sequencing-Whole Genome Sequencing
      • 2.5.1.9 Digital Droplet PCR (ddPCR)
    • 2.5.2 Clinical Applications of Next-generation Sequencing
  • 2.6 Oligonucleotide Array Platforms
  • 2.7 Emerging Cancer Personalized Medicine Market
  • 2.7.1 Predictive Cancer Molecular Diagnostics
  • 2.8 Companion Diagnostics
  • 2.9 Opportunities for Molecular Diagnostic Companies
  • 2.10 Liquid Biopsies
  • 2.11 Data Analysis
  • 2.12 In-house vs. Commercial Testing
  • 2.13 Multi-Gene Cancer Panels

3. Cancer Diagnostics Molecular Testing Market

  • 3.1 Market Description
    • 3.1.1 Market Overview for Molecular Diagnostics in Cancer Testing
    • 3.1.2 Laboratories Performing Molecular Diagnostics for Cancer Testing
    • 3.1.3 Competitive Landscape
      • 3.1.3.1 Pure Play Specialty Companies Performing Tumor MDx Analysis
      • 3.1.3.2 Mixed Specialty Cancer Diagnostic Labs
      • 3.1.3.3 General Clinical Reference Laboratories
      • 3.1.3.4 Diagnostic Device and Reagent Developers
      • 3.1.3.5 Companion Diagnostics Development in Partnership with a Pharmaceutical Company
    • 3.1.4 Sales and Marketing Strategies for Cancer Tests
      • 3.1.4.1 North American Market
      • 3.1.4.2 International Markets

4. Molecular Diagnostic Tests for Cancer

  • 4.1 Overview of Molecular Diagnostics for Cancer
    • 4.1.1 Cancer Statistics
    • 4.1.2 Treating Cancers
    • 4.1.3 Use of Genomics to Understand Cancer
    • 4.1.4 Molecular Diagnostic Tools Solutions
    • 4.1.5 Technology of Gene Expression Analysis
      • 4.1.5.1 Amplify and Detect Diminished Amounts of RNA Consistently
      • 4.1.5.2 Analyze Hundreds of Genes
      • 4.1.5.3 Employ Advanced Information Technology
  • 4.2 Breast Cancer Molecular Diagnostics
    • 4.2.1 Overview of Breast Cancer
    • 4.2.2 Breast Cancer Molecular Diagnostic Assays
      • 4.2.2.1 Ambry Genetics
      • 4.2.2.2 Agendia
        • 4.2.2.2.1 MammaPrint
      • 4.2.2.3 BGI
      • 4.2.2.4 Bioreference Labs
      • 4.2.2.5 BioTheronostics (part of BioMérieux)
        • 4.2.2.5.1 Breast Cancer Index
      • 4.2.2.6 Cancer Genetics, Inc. (CGI)
      • 4.2.2.7 Dako (part of Agilent Technologies)
      • 4.2.2.8 DiaSorin
      • 4.2.2.9 Fulgent Diagnostics
      • 4.2.2.10 Genetic Technologies Ltd.
      • 4.2.2.11 Genomic Health
        • 4.2.2.11.1 Oncotype DX
      • 4.2.2.12 Genoptix (part of Novartis)
      • 4.2.2.13 Invitae
      • 4.2.2.14 LabCorp
        • 4.2.2.14.1 BRCAssure® Tests
      • 4.2.2.15 Multiplicom
      • 4.2.2.16 Myriad Genetics
        • 4.2.2.16.1 BRACAnalysis®
        • 4.2.2.16.2 BART®
      • 4.2.2.17 Nanostring Technologies
        • 4.2.2.17.1 Prosigna
      • 4.2.2.18 Neogenomics
      • 4.2.2.19 Pathway Genomics
      • 4.2.2.20 Sophia Genetics
      • 4.2.2.21 Quest Diagnostics
        • 4.2.2.21.1 BRCAvantage Plus
      • 4.2.2.22 Ventana Medical Systems (Roche)
        • 4.2.2.22.1 HER2 Dual ISH DNA Probe Cocktail, INFORM
    • 4.2.3 Competitive Structure and Market Share Analysis
      • 4.2.3.1 Breast Cancer Molecular Diagnostic Testing Market Size
        • 4.2.3.1.1 Global Market
        • 4.2.3.1.2 U.S. Market
        • 4.2.3.1.3 European Market
    • 4.2.4 Market Drivers and Restraints
      • 4.2.4.1 Market Drivers
      • 4.2.4.2 Market Restraints
    • 4.2.5 Breast Cancer Molecular Diagnostic Testing Assay Market and Technology Trends
      • 4.2.5.1 Breast Cancer Molecular Diagnostic Testing Assay Market Trends
      • 4.2.5.2 Breast Cancer Molecular Diagnostic Testing Assay Technology Trends
      • 4.2.5.3 Breast Cancer Testing Assay Strategic Recommendations
  • 4.3 Colorectal Cancer Molecular Diagnostics Market
    • 4.3.1 Overview of Colorectal Cancer
    • 4.3.2 Colon Cancer Molecular Diagnostic Assays
      • 4.3.2.1 BRAF
      • 4.3.2.2 KRAS
      • 4.3.2.3 mSEPT9
      • 4.3.2.4 Screening Assays
        • 4.3.2.4.1 Overview of Stool-based DNA Assays
      • 4.3.2.5 Abbott
        • 4.3.2.5.1 Abbott RealTime KRAS Amplification Reagent Kit
        • 4.3.2.5.2 RealTime mS9 Colorectal Cancer
      • 4.3.2.6 Agendia
        • 4.3.2.6.1 ColoPrint
      • 4.3.2.7 Ambry Genetics
        • 4.3.2.7.1 ColoNext
      • 4.3.2.8 Bioreference Labs
      • 4.3.2.9 Cancer Genetics, Inc.
      • 4.3.2.10 Epigenomics
        • 4.3.2.10.1 Epi proColon
      • 4.3.2.11 Exact Sciences
        • 4.3.2.11.1 Cologuard
      • 4.3.2.12 Fulgent Diagnostics
      • 4.3.2.13 Genomic Health
        • 4.3.2.13.1 Oncotype DX colon
      • 4.3.2.14 Genomictree
      • 4.3.2.15 Genoptix (part of Novartis)
      • 4.3.2.16 Invitae
      • 4.3.2.17 LabCorp
      • 4.3.2.18 Myriad Genetics
        • 4.3.2.18.1 COLARIS
        • 4.3.2.18.2 COLARIS AP
      • 4.3.2.19 Neogenomics
      • 4.3.2.20 Novigenix
        • 4.3.2.20.1 Colox
      • 4.3.2.21 Pathway Genomics
        • 4.3.2.21.1 ColoTrue
      • 4.3.2.22 Qiagen
        • 4.3.2.22.1 therascreen KRAS RGQ PCR Kit
      • 4.3.2.23 Quest Diagnostics
        • 4.3.2.23.1 ColoVantage
      • 4.3.2.24 Roche
        • 4.3.2.24.1 cobas® KRAS Mutation Test
      • 4.3.2.25 Trovagene
        • 4.3.2.25.1 PCM KRAS Mutation Detection Test
    • 4.3.3 Competitive Structure and Market Share Analysis
      • 4.3.3.1 Colorectal Cancer Molecular Diagnostic Testing Market Size
      • 4.3.3.2 Market Drivers and Restraints
        • 4.3.3.2.1 Market Drivers
        • 4.3.3.2.2 Market Restraints
      • 4.3.3.3 Colon Cancer Molecular Diagnostic Testing Assay Market and Technology Trends
        • 4.3.3.3.1 Colon Cancer Molecular Diagnostic Testing Assay Market Trends
        • 4.3.3.3.2 Colon Cancer Molecular Diagnostic Testing Assay Technology Trends
        • 4.3.3.3.3 Colon Cancer Molecular Diagnostic Testing Assay Strategic Recommendations
    • 4.3.4 New Guidelines for Colorectal Cancer Molecular Testing
  • 4.4 Prostate Cancer Molecular Diagnostics Market
    • 4.4.1 Molecular Screening Assays for Prostate Cancer
      • 4.4.1.1 Hologic
        • 4.4.1.1.1 PROGENSA PCA3 Assay
      • 4.4.1.2 Bostwick Laboratories
        • 4.4.1.2.1 PCA3Plus
      • 4.4.1.3 Overview of PCA3
      • 4.4.1.4 MDx Health
        • 4.4.1.4.1 SelectMDx for Prostate Cancer
      • 4.4.1.5 Invitae
        • 4.4.1.5.1 Invitae Prostate Cancer Panel
      • 4.4.1.6 Neogenomics
        • 4.4.1.6.1 NeoLAB Prostate
    • 4.4.2 Molecular Assays Performed After Colorectal Biopsy
      • 4.4.2.1 Myriad Genetics
        • 4.4.2.1.1 Prolaris
      • 4.4.2.2 Genomic Health
        • 4.4.2.2.1 Oncotype DX Genomic Prostrate Score
      • 4.4.2.3 MDxHealth (ConfirmMDx)
      • 4.4.2.4 Bostwick Laboratories (ProstaVysion)
      • 4.4.3.5 MDNA Life Sciences
        • 4.4.3.5.1 Prostate Core Mitomic Test
      • 4.4.2.6 GenomeDx
        • 4.4.2.6.1 Decipher
    • 4.4.3 Competitive Structure and Market Share Analysis
    • 4.4.4 Market Drivers and Restraints
      • 4.4.4.1 Market Drivers
      • 4.4.4.2 Market Restraints
    • 4.4.5 Prostate Cancer Molecular Diagnostic Testing Assay Market and Technology Trends
      • 4.4.5.1 Prostate Cancer Molecular Diagnostic Testing Assay Market Trends
      • 4.4.5.2 Prostate Cancer Molecular Diagnostic Testing Assay Technology Trends
  • 4.5 Ovarian Cancer
    • 4.5.1 Incidence of Ovarian Cancer
    • 4.5.2 Key Players in Ovarian Testing Market
      • 4.5.2.1 Ambry Genetics
      • 4.5.2.2 Myriad Genetics
      • 4.5.2.3 Market Drivers and Restraints
        • 4.5.2.3.1 Market Drivers
        • 4.5.2.3.2 Market Restraints
  • 4.6 Lung Cancer
    • 4.6.1 Incidence of Lung Cancer
    • 4.6.2 Pharmacogenomics and Cancer
    • 4.6.3 Lung Cancer Molecular Diagnostics Assays
      • 4.6.3.1 Genoptix (a Novartis company)
        • 4.6.3.1.1 NexCourse NSCLC
      • 4.6.3.2 Qiagen
        • 4.6.3.2.1 therascreen EGFR RGQ PCR Kit
      • 4.6.3.3 Roche
        • 4.6.3.3.1 cobas® EGFR Mutation Test v2
      • 4.6.3.4 Epigenomics
        • 4.6.3.4.1 Epi proLung® BL Reflex Assay
      • 4.6.3.5 Myriad Genetics
        • 4.6.3.5.1 myPlan™ Lung Cancer
      • 4.6.3.6 Quest Diagnostics
        • 4.6.3.6.1 Lung Cancer Mutation Panel
      • 4.6.3.7 Rosetta Genomics
        • 4.6.3.7.1 OncoGxLung
      • 4.6.3.8 Trovagene
        • 4.6.3.8.1 PCM EGFR Mutation Detection Test
      • 4.6.3.9 Veracyte, Inc.
        • 4.6.3.9.1 Percepta
      • 4.6.3.10 Accugenomics
        • 4.6.3.10.1 Lung Cancer Risk Test (LCRT-AGX)
    • 4.6.4 Competitive Space
  • 4.7 Melanoma
    • 4.7.1 bioMérieux
      • 4.7.1.1 THxID™ BRAF
    • 4.7.2 Roche
      • 4.7.2.1 cobas®
    • 4.7.3 Myriad
      • 4.7.3.1 myPath™ Melanoma
    • 4.7.4 Trovagene
      • 4.7.4.1 PCM BRAF Mutation Detection Test
  • 4.8 Molecular Diagnostic Assays for Other Types of Cancers
    • 4.8.1 Accugenomics
      • 4.8.1.1 Standardized BCR-ABL Molecular Diagnostics Test
    • 4.8.2 Ambry Genetics
      • 4.8.2.1 PancNext
      • 4.8.2.2 PGLNext
      • 4.8.2.3 RenalNext
    • 4.8.3 Asuragen
      • 4.8.3.1 QuantideX® qPCR BCR-ABL IS Kit
    • 4.8.4 DiaSorin
      • 4.8.4.1 PML-RARA Detection bcr1,3 and Discrimination bcr2
  • 4.9 Panels Testing Multiple Cancers
    • 4.9.1 Ambry Genetics
      • 4.9.1.1 CancerNext
      • 4.9.1.2 CancerNext-Expanded
    • 4.9.2 Biotheranostics
      • 4.9.2.1 CancerTYPE ID
    • 4.9.3 Cancer Genetics, Inc. (CGI)
    • 4.9.4 Color Genomics
      • 4.9.4.1 Color Test
    • 4.9.5 Counsyl Labs
    • 4.9.6 Guardant Health
    • 4.9.7 Multiplicom
      • 4.9.7.1 SOMATIC 1 MASTR™ Plus Dx
    • 4.9.8 Myriad Genetics
      • 4.9.8.1 myRisk™ Hereditary Cancer
    • 4.9.9 Pathway Genomics
      • 4.9.9.1 CancerIntercept™ Detect
    • 4.9.10 Quest Diagnostics
      • 4.9.10.1 OncoVantage® Solid Tumor Mutation Analysis
    • 4.9.11 Rosetta Genomics
      • 4.9.11.1 OncoGxOne™
  • 4.10 Potential new Entrants to the Market
    • 4.10.1 Illumina
    • 4.10.2 Metabiomics
    • 4.10.3 Orion Genomics
    • 4.10.4 Siemens
    • 4.10.5 VolitionRx

5. Business

  • 5.1 Technology and Market Trends
    • 5.1.1 Technology Trends
    • 5.1.2 Market Trends
  • 5.2 M&A Activity
  • 5.3 Partnerships
  • 5.4 Summary of Market Strengths, Weaknesses, Opportunities and Threats
    • 5.4.1 Industry Challenges and Strategic Recommendations
    • 5.4.2 Commercialization of Molecular Diagnostic Products
  • 5.5 Intellectual Property Rights
    • 5.5.1 BRCA1 and BRCA2 Gene Patents
    • 5.5.2 Current Patent Disputes

6. Reimbursement and Billing

  • 6.1 Overview
  • 6.2 Trends in Reimbursement Practice
    • 6.2.1 Medicare Reimbursement
    • 6.2.2 Analysis of ROI for MDx Tests for Cancer Using Medicare Reimbursement Rules
  • 6.3 Trends in Patient Care and Reimbursement
  • 6.4 Revenue Threats
    • 6.4.1 Three Areas for Denial of Claims by Biomarkers
  • 6.5 Billing
    • 6.5.1 Medicare Billing Procedures
    • 6.5.2 Medicare CPT Coding Rules for Cancer Biomarkers

7. Government Regulation

  • 7.1 U.S. Food and Drug Administration
  • 7.2 CLIA Regulations
  • 7.3 Clinical Laboratory Improvement Act
  • 7.4 State Licensing for Service Laboratories
  • 7.5 510(k) Clearance
  • 7.6 Pre-Market Approval
  • 7.7 ASRs
  • 7.8 What Regulatory Guidance is Needed for Companion Biomarkers?
  • 7.9 U.S. Patent and Trademark Office
  • 7.10 IRB Approval in Clinical Trials
  • 7.11 Microarray Quality Control
  • 7.12 ER and PR Proficiency Testing

8. Company Profiles

  • 8.1 Abbott Molecular Diagnostics
  • 8.2 AccuGenomics, Inc.
  • 8.3 Agendia
  • 8.4 Ambry Genetics
  • 8.5 Asuragen
  • 8.6 BGI
  • 8.7 Biodesix
  • 8.8 bioMérieux
  • 8.9 Bioreference Labs
  • 8.10 bioTheranostics
  • 8.11 Cancer Genetics, Inc.
  • 8.12 Counsyl
  • 8.13 Dako (an Agilent Technologies company)
  • 8.14 DiaSorin
  • 8.15 Epigenomics
  • 8.16 Exact Sciences Corporation
  • 8.17 Exiqon
  • 8.18 Flatiron Health
  • 8.19 Fulgent Diagnostics
  • 8.20 Genomic Health, Inc.
  • 8.21 Genomictree
  • 8.22 Genoptix, Inc. (Novartis)
  • 8.23 HTG Molecular Diagnostics
  • 8.24 Guardant Health
  • 8.25 Hologic
  • 8.26 Illumina
  • 8.27 Invitae
  • 9.28 LabCorp
  • 8.29 MDxHealth
  • 8.30 Myriad Genetics, Inc.
  • 8.31 Nanostring
  • 8.32 Neogenomics
  • 8.33 Nuvera Biosciences
  • 8.34 Orion Genomics
  • 8.35 Pathway Genomics
  • 8.36 Qiagen
  • 8.37 Quest Diagnostics
  • 8.38 Roche Molecular Systems
  • 8.39 Rosetta Genomics Ltd.
  • 8.40 Sophia Genetics
  • 8.41 Trovagene

Appendix 1: Definition of Terms for Molecular Diagnostics

Appendix 2: Standard Cancer Therapeutic Panels

INDEX OF FIGURES

  • Figure 2.1: Finding Genes with Microassays
  • Figure 2.2: Use of Microassays for Studying Gene Expression
  • Figure 2.3: Finding New Drugs with Microarrays
  • Figure 2.4: Using DNA Microarrays to Compare Cancer and Normal Cells
  • Figure 2.5: Microarrays for Prediction of Survival in Cancer
  • Figure 2.6: ddPCR Using a Single Color Probe
  • Figure 2.7: ddPCR Using Two Probe Colors
  • Figure 2.8: BEAMing Method of ctDNA Detection
  • Figure 2.9: Using Gene Expression Patterns to Chose Treatment
  • Figure 3.1: Molecular Diagnostic Markets for Cancer Testing Globally, 2015
  • Figure 3.2: Molecular Diagnostic Markets for Cancer Testing in the U.S., 2015
  • Figure 3.3: Market Share for Key Companies in the Global Molecular Diagnostics Cancer Testing Market
  • Figure 3.4: Market Growth and Evolution of MDx Cancer Biomarkers
  • Figure 4.1: Using DNA Microassays to Measure Gene Expression
  • Figure 4.2: Schematic of Molecular Diagnostics for Studying Gene Expression in Patients
  • Figure 4.3: Action of Herceptin in Breast Cancer Patients
  • Figure 4.4: Analysis of Cancer Tissue by Microarray
  • Figure 4.5: HNPCC Mutation Increases Risk of Cancer
  • Figure 4.6: APC Mutation Increases Risk of Cancer
  • Figure 4.7: Prostate-Specific Membrane Antigen
  • Figure 4.8: PCA3 Score Nomogram
  • Figure 4.9: Ovarian Cancer Types
  • Figure 4.10: Targets for Therapy-Mutations Associated with Lung Cancer
  • Figure 4.11: Molecular Subsets of Lung Cancer
  • Figure 5.1: FDA Co-Developed Products as a Model for Collaboration

INDEX OF TABLES

  • Table 2.1: Types of Molecular Tests and Types of Genetic Variants Detected
  • Table 2.2: Use of Cancer Biomarkers to Enhance Patient Care
  • Table 2.3: Targeted Drug Therapies for Cancers
  • Table 2.4: Select Genes and Cancer Risk
  • Table 2.5: Use of Cancer Biomarkers in Drug Development
  • Table 2.6: Utility of Biomarkers as Companion Diagnostics to Drug Development
  • Table 2.7: FDA Approved Companion Diagnostics
  • Table 2.8: Recommended Databases for Interpreting Somatic Mutation Results in Cancer
  • Table 3.1: Specific Diagnostic Products Categories Comprising the Cancer Diagnostic Market
  • Table 3.2: Global Market for Molecular Diagnostics Cancer Testing, 2012-2021
  • Table 3.3: U.S. Market for Molecular Diagnostics Cancer Testing, 2012-2021
  • Table 3.4: Molecular Diagnostic Markets for Cancer Testing, 2015
  • Table 3.5: Key Companies in the Global Molecular Diagnostics Cancer Testing Market
  • Table 3.6: Highlights of the Cancer Diagnostic Testing Segment
  • Table 3.7: Highlights of Certified Clinical Labs Specializing in Cancer Genetics and Molecular Diagnostic Services
  • Table 3.8: Business Factors Influencing Advanced Oncology Testing Services
  • Table 3.9: Strategies for Marketing Cancer Diagnostic Products
  • Table 3.10: Key Elements of MDx Diagnostic Companies Marketing Plan
  • Table 4.1: FDA Approved Cancer Tests
  • Table 4.2: Estimates for the Leading Sites of New Cancer Cases in the U.S. by Gender, 2016
  • Table 4.3: Estimates for the Leading Sites of Cancer Deaths in the U.S. by Gender, 2016
  • Table 4.4: Molecular Diagnostic Technologies
  • Table 4.5: Breast Cancer Overview
  • Table 4.6: Overview of HER2/neu and Herceptin
  • Table 4.7: Key Players in the Breast Cancer Molecular Diagnostic Space
  • Table 4.8: FDA-Approved Breast Cancer Molecular Diagnostic Tests on the Market
  • Table 4.9: MammaPrint: Key Features
  • Table 4.10: Clinical Utility and Health Economic Benefits of Oncotype DX
  • Table 4.11: Oncotype DX Overview
  • Table 4.12: Major Laboratory Testing Companies Marketing Breast Cancer Molecular Diagnostic Tests, 2015
  • Table 4.13: Global Market for Breast Cancer Molecular Diagnostic Testing, 2012-2021
  • Table 4.14: U.S. Market for Breast Cancer Molecular Diagnostic Testing, 2012-2021
  • Table 4.15: Breast Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked in Order of Impact
  • Table 4.16: Breast Cancer Molecular Diagnostic Testing Market: Market Restraints Ranked in Order of Impact
  • Table 4.17: Summary of Strengths, Weaknesses, Opportunities and Threats of the Breast Cancer Molecular Diagnostic Market
  • Table 4.18: Colorectal Cancer Overview
  • Table 4.19: Key Players in the Breast Cancer Molecular Diagnostic Space
  • Table 4.20: FDA-Approved and/or CE-marked Colorectal Cancer Molecular Diagnostic Tests on the Market
  • Table 4.21: KRAS Assays by Analytical Type
  • Table 4.22: KRAS Mutation Analysis Summary
  • Table 4.23: KRAS and BRAF in Clinical Use
  • Table 4.24: Key Players in the Colorectal Cancer Molecular Diagnostic Space
  • Table 4.25: NexCourse CRC Test Offering and Treatment Direction
  • Table 4.26: Global Market for Molecular Diagnostic Colon Cancer Testing, 2012-2021
  • Table 4.27: U.S. Market for Molecular Diagnostic Colon Cancer Testing, 2012-2021
  • Table 4.28: Colon Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked in Order of Impact
  • Table 4.29: Colon Cancer Molecular Diagnostic Testing Market: Market Restraints Ranked in Order of Impact
  • Table 4.30: Summary of Strengths, Weaknesses, Opportunities and Threats of the Colon Cancer Market
  • Table 4.31: Stages in Prostate Cancer Discovery and Diagnosis
  • Table 4.32: Corporate Players in the Prostate Cancer Molecular Diagnostic Space
  • Table 4.33: Prostate Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked in Order of Impact
  • Table 4.34: Prostate Cancer Molecular Diagnostic Testing Market: Market Restraints Ranked in Order of pact
  • Table 4.35: Summary of Strengths, Weaknesses, Opportunities and Threats of the Prostate Cancer Molecular Diagnostic Market
  • Table 4.36: Ovarian Cancer Molecular Diagnostic Testing Market: Market Drivers in Order of Impact
  • Table 4.37: Ovarian Cancer Molecular Diagnostic Testing Market: Market Restraints in Order of Impact
  • Table 4.38: Lung Cancer Survival Rates
  • Table 4.39: Lung Cancer Facts
  • Table 4.40: Pharmacogenetic Markers for Select Cancer Drugs
  • Table 4.41: Potential of Cancer Biomarkers in Drug Delivery and Development
  • Table 5.1: Technology Trends in Cancer Testing
  • Table 5.2: Trends in Theranostics
  • Table 5.3: Market Trends in Cancer Testing
  • Table 5.4: Molecular Diagnostics Cancer Market: Market Drivers Ranked in Order of Impact
  • Table 5.5: Molecular Diagnostics Cancer Market: Market Restraints Ranked in Order of Impact
  • Table 5.6: Summary of Strengths, Weaknesses, Opportunities and Threats of the Glucose Point of Care Market
  • Table 5.7: Molecular Diagnostics Cancer Market: Strategic Recommendations on Molecular Diagnostic Sector Business Functions
  • Table 5.8: Total U.S. Molecular Diagnostics Cancer Market: Impact of Top Industry Challenges
  • Table 5.9: Key Elements for Business Competition in Gene Expression Profiling for Cancer
  • Table 6.1: Factors Determining Third-Party Payment for Advanced Cancer Tests
  • Table 7.1: Rules that Affect the Ability of a Cancer Diagnostic Service Lab to Conduct Business
  • Table 7.2: Focus Areas for the FDA Critical Path Initiative
Back to Top